Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) has released its unaudited interim consolidated financial statements for the six-month period ended June 30, 2026, alongside updated Phase II clinical data for Ruvidar® (TLD-1433) in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. The company reported a narrowing net loss and improved gross margins year-over-year, while disclosing that 65.2% of evaluable patients achieved a complete response at any point in time. Investors are also watching the company's plans to file regulatory submissions and launch a combination cohort with Ferring Pharmaceuticals' Adstiladrin® (nadofaragene firadenovec-vncg), subject to FDA approval.

Key Points

  • Theralase® Technologies Inc. (TSXV: TLT / OTCQB: TLTFF) released Q2 2026 financial statements and a clinical update
  • Net loss narrowed to $2,093,926 for H1 2026, down 14% from $2,423,234 in H1 2025, primarily due to reduced Study II research and development spending
  • 65.2% complete response rate reported among 89 evaluable BCG-Unresponsive NMIBC CIS patients in Study II Cohort 1; cash position reached $5,260,832 as of June 30, 2026
  • Investors may be watching the anticipated NDS and NDA regulatory submissions planned for Q4 2026 and Cohort 2 combination study preparation

H1 2026 Financial Results: Narrowing Losses and Improved Gross Margin

Total revenue for the six-month period ended June 30, 2026, decreased 5% to $296,927 from $310,933 in the same period in 2025. However, gross margin improved to 50% of revenue ($149,946) from 42% ($131,967) a year earlier, as cost of sales fell. Administrative expenses edged up 1% to $1,003,798, while net research and development expenses declined 25% to $1,101,126, attributed to lower Study II patient enrolment and treatment costs. Cash stood at $5,260,832 as of June 30, 2026, bolstered by a $3,555,000 brokered private placement that closed on August 24, 2026.

Ruvidar® Study II Cohort 1 Clinical Results in BCG-Unresponsive NMIBC

Of 89 patients evaluable for the primary endpoint, 58 achieved a complete response, representing a 65.2% complete response rate (95% CI: 49.4–80.9%). Total response, including incomplete responses, was 73.0%. For the secondary endpoint at 450 days, 40.4% of responding patients maintained complete response at 15 months. At extended follow-up, the Kaplan-Meier estimated probability of remaining cancer-free at one, two, and three years was 48.6%, 34.5%, and 25.4%, respectively. Theralase® reported a 100% safety profile across 82 completers, with treatment-emergent adverse events resolving within one month.

Cohort 2 Combination Study and Regulatory Submission Timeline

Theralase® and Ferring Pharmaceuticals are preparing to launch Cohort 2, combining light-activated Ruvidar® with Adstiladrin®, subject to FDA approval. The company intends to commence rolling submissions of a New Drug Submission to Health Canada and a New Drug Application to the FDA in Q4 2026, with marketing decisions anticipated in 2027. The company is also pursuing licensing arrangements, collaborative research partnerships, and commercialisation opportunities across multiple geographic regions for Ruvidar®.

Rutherrin Pipeline and GLP Toxicology Milestones

Theralase® disclosed plans to complete Good Laboratory Practices toxicology studies for its pipeline compound Rutherrin by Q4 2026, aiming to determine the Maximum Tolerated Dose and Human Equivalent Dose. Subject to regulatory approval, the company intends to commence Phase 0/I/II adaptive clinical studies in 2027, targeting indications including Glioblastoma Multiforme, Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, pancreatic cancer, colorectal cancer, and Herpes Simplex Virus-1.